Berrylin J. Ferguson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Berrylin J. Ferguson has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Angela Powell-Davis
1 shared publicationElaine Rubinstein
University of Pittsburgh School of Medicine Eye and Ear Institute and the Department of Otolaryngology Pittsburgh Pennsylvania
1 shared publicationSuchitra Paramaesvaran
University of Pittsburgh School of Medicine Eye and Ear Institute and the Department of Otolaryngology Pittsburgh Pennsylvania
1 shared publication
Latest Publications
- 1 October 2003
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 36 (5) , 771-779
New horizons in the management of allergy.
- 1 October 2003
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 36 (5) , 771-779
New horizons in the management of allergy.
- 1 June 2003
- Published by Wolters Kluwer Health in Current Opinion in Otolaryngology & Head and Neck Surgery
- Vol. 11 (3) , 192-195
The link between upper and lower respiratory disease
The upper and lower airways are connected anatomically, physiologically, and immunologically. Epidemiologic studies provide strong evidence of associated dysfunction. Therapeutic modalities with indications for treatment of one portion of the airway are frequently used for the other. These include antihistamines, inhaled or nasal steroids, cromolyns, and most recently leukotriene receptor antagonists. Studies of the upper airway show that upper airway impairment with allergic rhinitis affects the lower airway and that pharmacological treatment of allergic rhinitis can prevent seasonal asthma. Recently, single-agent allergy sensitization has been shown to prevent the development of asthma. Conflicting data exist regarding the affect of sinus surgery on asthma severity. This review is intended to provide an update of our knowledge of the upper and lower airway connection, highlighting articles published within the last year.
- 1 June 2003
- Published by Wolters Kluwer Health in Current Opinion in Otolaryngology & Head and Neck Surgery
- Vol. 11 (3) , 192-195
The link between upper and lower respiratory disease
The upper and lower airways are connected anatomically, physiologically, and immunologically. Epidemiologic studies provide strong evidence of associated dysfunction. Therapeutic modalities with indications for treatment of one portion of the airway are frequently used for the other. These include antihistamines, inhaled or nasal steroids, cromolyns, and most recently leukotriene receptor antagonists. Studies of the upper airway show that upper airway impairment with allergic rhinitis affects the lower airway and that pharmacological treatment of allergic rhinitis can prevent seasonal asthma. Recently, single-agent allergy sensitization has been shown to prevent the development of asthma. Conflicting data exist regarding the affect of sinus surgery on asthma severity. This review is intended to provide an update of our knowledge of the upper and lower airway connection, highlighting articles published within the last year.
- Open Access
- 1 September 2001
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 125 (3) , 253-260
A Study of the Effect of Nasal Steroid Sprays in Perennial Allergic Rhinitis Patients with Rhinitis Medicamentosa
OBJECTIVE: To determine if rebound congestion can be reduced with concomitant nasal steroid spray usage.STUDY DESIGN AND SETTING: Randomized, double blind, controlled single center study.PARTICIPANTS: Twenty subjects with perennial allergic rhinitis with nasal congestion.INTERVENTION: All subjects received 3 weeks of twice‐daily oxymetazoline. After 2 weeks, subjects were randomized to 2 additional weeks of concomitant budesonide aqueous nasal spray (n = 9) or placebo (n = 10). In the sixth week, all sprays were stopped.RESULTS: Both groups showed subjective and objective evidence of rebound congestion 24 hours after cessation of oxymetazoline (P < 0.05). Subjective rebound congestion resolved in 48 hours in the budesonide aqueous nasal spray group but persisted for over 1 week in the placebo group.CONCLUSION: Rebound congestion is objectively present in patients with perennial allergic rhinitis after 3 weeks of oxymetazoline spray. Rebound congestion is reduced by concomitant budesonide aqueous nasal spray use.SIGNIFICANCE: This study supports the common clinical practice of nasal steroid sprays to ameliorate rebound congestion concomitant with and after cessation of topical decongestant sprays.
- 1 September 2001
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 125 (3) , 253-260
Open AccessA Study of the Effect of Nasal Steroid Sprays in Perennial Allergic Rhinitis Patients with Rhinitis Medicamentosa
OBJECTIVE: To determine if rebound congestion can be reduced with concomitant nasal steroid spray usage.STUDY DESIGN AND SETTING: Randomized, double blind, controlled single center study.PARTICIPANTS: Twenty subjects with perennial allergic rhinitis with nasal congestion.INTERVENTION: All subjects received 3 weeks of twice‐daily oxymetazoline. After 2 weeks, subjects were randomized to 2 additional weeks of concomitant budesonide aqueous nasal spray (n = 9) or placebo (n = 10). In the sixth week, all sprays were stopped.RESULTS: Both groups showed subjective and objective evidence of rebound congestion 24 hours after cessation of oxymetazoline (P < 0.05). Subjective rebound congestion resolved in 48 hours in the budesonide aqueous nasal spray group but persisted for over 1 week in the placebo group.CONCLUSION: Rebound congestion is objectively present in patients with perennial allergic rhinitis after 3 weeks of oxymetazoline spray. Rebound congestion is reduced by concomitant budesonide aqueous nasal spray use.SIGNIFICANCE: This study supports the common clinical practice of nasal steroid sprays to ameliorate rebound congestion concomitant with and after cessation of topical decongestant sprays.